Huadong Medicine (SHE:000963) subsidiary Hangzhou Sino-US Huadong Pharmaceutical obtained clinical trial approvals for two variants of its Roflumilast cream, according to a Monday filing with the Shenzhen Stock Exchange.
The 0.15% Roflumilast cream is indicated for mild to moderate atopic dermatitis in patients 6 years and older.
The 0.3% variant is indicated for patients with plaque psoriasis in patients 6 years and older, including intertriginous areas, where two body parts rub against each other, the filing said.
Shares closed 8% higher during Monday's trading.
Price (RMB): ¥34.99, Change: ¥+2.6, Percent Change: +7.96%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments